Methoxyethyl-modified intercellular adhesion molecule-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporin-induced nephrotoxicity

Transplantation

Volumn 79, Issue 4, 2005, Pages 401-408

  Chen, Wenhau ^a   Langer, Robert M ^a   Janczewska, Slawa ^a   Furian, Lucrezia ^a   Geary, Richard ^b   Qu, Xuimei ^a   Wang, Mouer ^a   Verani, Regina ^a   Condon, Tom ^b   Stecker, Kim ^b   Bennett, C Frank ^b   Stepkowski, Stanislaw M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; ICAM 1; Immunosuppression; Ischemia reperfusion injury; Kidney; Transplantation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLOSPORIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; METHYL GROUP; PHOSPHOROTHIOIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; ISCHEMIC REPERFUSION; ISOGRAFT; KIDNEY ALLOGRAFT REJECTION; LEUKOCYTE; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TISSUE INJURY;

ANIMALS; CELLS, CULTURED; CYCLOSPORINE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED ACI; RATS, INBRED LEW; REPERFUSION INJURY; THIONUCLEOTIDES; TRANSPLANTATION, HOMOLOGOUS;

EID: 20044394365     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000149505.53886.27     Document Type: Article

References (47)

1. Crooke RM, Graham MJ, Cooke ME, et al. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 1995; 275: 462.
2. Mirabelli CK, Crooke ST. Antisense oligonucleotides in the context of modem molecular drug discovery and development. In: Antisense research and application. Boca Raton, CRC Press 1993, p. 7.
3. Akhtar S, Kole R, Juliano RL. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci 1991; 49: 1793.
4. Milligan JF, Matteucci MD, Martin JC. Current concepts in antisense drug design. J Med Chem 1993; 36: 1923.
5. Henry SP, Geary RS, Yu R, Levin AA. Drug properties of second generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs 2001; 2: 1444.
6. Springer TA. The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors. Annu Rev Cell Biol 1990; 6: 359.
7. Lacha J, Bushell A, Smetana K, et al. Intercellular cell adhesion molecule-1 and selectin ligands in acute cardiac allograft rejection: a study on gene-deficient mouse models. J Leukoc Biol 2002; 71: 311.
8. Stepkowski SM. Development of antisense oligodeoxynucleotides for transplantation. Curr Opin Mol Ther 2000; 2: 304.
9. Stepkowski SM, Wang ME, Condon TP, et al. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplantation 1998; 66: 699.
10. Chen W, Bennett CF, Wang ME, et al. Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury. Transplantation 1999; 68: 880.
11. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
12. Bennett WM. Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Ren Fail 1996; 18: 453.
13. Andoh TF, Bennett WM. Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 1998; 7: 265.
14. Knight JA, Cheung AK, Pieper RK, et al. Increased urinary lipoperoxide levels in renal transplant patients. Ann Clin Lab Sci 1989; 19: 238.
15. Ahmed SS, Napoli KL, Strobel HW. Oxygen radical formation during cytochrome P450-catalyzed cyclosporine metabolism in rat and human liver microsomes at varying hydrogen ion concentrations. Mol Cell Biochem 1995; 151: 131.
16. Bennett CF, Condon TP, Grimm S, et al. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 1994; 152: 3530.
17. Bennett CF, Chiang MY, Chan H, et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41: 1023.
18. Stepkowski SM, Tu Y, Condon TC, et al. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol 1994; 153: 5336.
19. Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419.
20. Chirgwin JM, Przybyla AE, MacDonald RJ, et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294.
21. Fisher B, Lee S. Microvascular surgical technique in research: special reference to renal transplantation in the rat. Surgery 1965; 58: 904.
22. Khatsenko O, Morgan R, Truong L, et al. Absorption of antisense oligonucleo tides in rat intestine: effect of chemistry and length. Antisense Nucleic Acids Drug Dev 2000; 10: 35.
23. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203.
24. Liang H, Reich CF, Pisetsky DS, et al. The role of cell surface receptors in the activation of human B cells by phosphorothioate oligonucleotides. J Immunol 2000; 165: 1438.
25. Krieg AM. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1999; 1489: 107.
26. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000; 164: 944.
27. Agrawal S, Zhang X, Lu Z, et al. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 1995; 50: 571.
28. Crooke ST, Graham MJ, Zuckerman JE, et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 1996; 277: 923.
29. English J, Evan A, Houghton DC, et al. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135.
30. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059.
31. Cossum PA, Truong L, Owens SR, et al. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 1994; 269: 89.
32. Glover JM, Leeds JM, Mant TG, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282: 1173.
33. Levin AA, Monteith DK, Leeds JM, et al. Toxicity of oligodeoxynucleotide therapeutic agents. Crooke ST, ed. Antisense research applications. Berlin, Springer-Verlag 1998, p. 169.
34. Williams P, Lopez H, Britt D, et al. Characterization of renal ischemia-reperfusion injury in rats. J Pharmacol Toxicol Methods 1997; 37: 1.
35. Fuggle SV, Koo DD. Cell adhesion molecules in clinical renal transplantation. Transplantation 1998; 65: 763.
36. Bonventre JV. Mechanisms of ischemic acute renal failure. Kidney Int 1993; 43: 1160.
37. Rijcken E, Krieglstein CF, Anthoni C, et al. ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Cut 2002; 51: 529.
38. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 1990; 4: 554.
39. Baud L, Ardaillou R. Involvement of reactive oxygen species in kidney damage. Br Med Bull 1993; 49: 621.
40. Serino F, Grevel J, Napoli KL, et al. Oxygen radical formation by the cytochrome P450 system as a cellular mechanism for cyclosporine toxicity. Transplant Proc 1994; 26: 2916.
41. Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998; 65: 313.
42. Avdonin PV, Cottet-Maire F, Afanasjeva GV, et al. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999; 55: 2407.
43. Healy E, Dempsey M, Lally C, et al. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998; 54: 1955.
44. Ortiz A, Lorz C, Catalan M, et al. Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. Kidney Int Suppl 1998; 68: S25-S29.
45. Vaziri ND, Ni Z, Zhang YP, et al. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int 1998; 54: 482.
46. Mampaso F, Sanchez-Madrid F, Marcen R, et al. Expression of adhesion molecules in allograft renal dysfunction. A distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity. Transplantation 1993; 56: 687.
47. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835.